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Background: Deep transcranial magnetic stimulation (DTMS) is a non-invasive method of stimulating widespread
cortical areas and, presumably, deeper neural networks. The current study assessed the effects of DTMS in the
treatment of substance use disorders (SUD) using a systematic review.
Methods: Electronic literature search (PsycInfo, Medline until April 2017) identified k = 9 studies (k = 4 randomized-
controlled trials, RCTs, with inactive sham and k = 5 open-label studies). DTMS was most commonly applied using
high frequency/intensity (10–20 Hz/100–120% of the resting motor threshold, MT) protocols for 10–20 daily
sessions in cases with alcohol, nicotine or cocaine use disorders. The outcome measures were craving and
dependence (according to standardized scales) or consumption (frequency, abstinence or results of biological
assays) at the end of the daily treatment phases and at the last follow-up.
Results: Acute and longer-term (6–12 months) reductions in alcohol craving were observed after 20 sessions
(20 Hz, 120% MT) relative to baseline in k = 4 open-label studies with comorbid SUD and major depressive disorder
(MDD). In k = 2 RCTs without MDD, alcohol consumption acutely decreased after 10–12 sessions (10–20 Hz, 100–
120% MT) relative to baseline or to sham. Alcohol craving was reduced only after higher frequency/intensity DTMS
(20 Hz, 120% MT) relative to sham in k = 1 RCT. Nicotine consumption was reduced and abstinence was increased
after 13 sessions (10 Hz, 120% MT) and at the 6-month follow-up relative to sham in k = 1 RCT. Cocaine craving was
reduced after 12 sessions (15 Hz, 100% MT) and at the 2-month follow-up relative to baseline in k = 1 open-label
study while consumption was reduced after 12 sessions (10 Hz, 100% MT) relative to baseline but not to sham in k
= 1 RCT.
Conclusions: High-frequency DTMS may be effective at treating some SUD both acutely and in the longer-term.
Large RCTs with inactive sham are required to determine the efficacy and the optimal stimulation parameters of
DTMS for the treatment of SUD.
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Table 1 Systematic search strategy for primary studies
k studies Search terms Databases (time frame)
133 TI (“deep transcranial magnetic
stimulation” OR “deep repetitive
transcranial magnetic stimulation”
OR deep rTMS OR deepTMS OR
deep TMS OR H-coil)
PsycInfo, Medline (OVID)
(any date – 28.04.2017)
Search was performed in English with no language restrictions or any
other limits
k number of studies, rTMS repetitive transcranial magnetic stimulation, TI title,
TMS transcranial magnetic stimulation
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Deep transcranial magnetic stimulation (DTMS) with
the H-coil system is a relatively novel non-invasive brain
stimulation method [1]. Since 2013 DTMS is approved
by the US Food and Drug Administration (FDA) for
treatment-resistant unipolar major depression (MDD).
The most commonly utilized DTMS protocol involves
high-frequency (18–20 Hz) and high intensity (120% of
the resting motor threshold, MT) stimulation delivered
for 20 days. Such protocol has acute antidepressant [2,
3] as well as anxiolytic [4] properties in MDD, and tends
to improve working memory and executive functioning
in MDD and schizophrenia [5, 6].
The current focus in the field is to test other thera-
peutic applications of DTMS beyond MDD [7, 8]. One
such application involves the use of DTMS for treatment
of substance use disorders (SUD). Since SUD are diffi-
cult to treat with only modest responses to available
therapies [9], they increase the burden of disease, in par-
ticular in comorbid conditions [10]. The evidence to
date suggests that depending on the protocols and the
coils, the non-invasive, repetitive brain stimulation
methods appear to affect the neuroplasticity around the
coil as well as throughout the brain [9, 11]. The func-
tional reorganization could affect behaviors related to
addiction, including reduction in craving and a better
regulation of the compulsive desire to consume the sub-
stances [9, 11]. The unique structure of the H-coils is of
particular interest because it allows to repetitively stimu-
late the entire cortex in contrast to other systems offer-
ing a more focal stimulation (for example, the figure of
eight, F8-coil, used for repetitive transcranial magnetic
stimulation, rTMS). Such a broad stimulation with
H-coils could increase the electrical field in deeper, sub-
cortical brain regions [12, 13]. Therefore, DTMS with
H-coils is a promising candidate for treatment of various
SUD that affect similar neural circuitry (deeper cortico-
striatal pathways) [14] and share numerous molecular
targets [15].
The aim of the current study was to systematically
assess the effects of DTMS in the treatment of SUD.Methods
The current review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [16].Systematic search strategy and study selection
An electronic search of PsycInfo, Medline, and Google
Scholar (until April 2017) identified k = 133 studies
(Table 1).
Nine studies [17–25] met the following inclusion
criteria:1) DTMS applied in cases with any SUD using any
type of H-coil,
2) any study designs including double-blind randomized
controlled trials (RCTs) with inactive sham groups or
open-label designs,
3) parallel designs in case of RCTs (to prevent any
carry-over effects),
4) any number of cases/study (including single case
studies),
5) SUD assessed at baseline and after DTMS using any
method (standardized scales or biological assays).
Studies were excluded if they did not assess SUD
(k = 55/83), did not include human data (k = 10/83) or
were reviews (k = 9/83; Fig. 1).
Data coding and outcome measures
Data from k = 9 studies were coded by the authors inde-
pendently and any inconsistencies were resolved by con-
sensus. Study details (participant characteristics, study
designs, SUD assessment methods, and stimulation
parameters) are shown in Tables 2, 3 and 4.
The primary outcome measures were craving and
dependence (assessed with standardized scales listed in
Table 3) or consumption (use frequency, abstinence rate
or results of urine, blood or hair analysis; Table 3) at the
end of the acute (daily) treatment with DTMS and at the
last follow-up. Since some studies included samples with
comorbid MDD, the secondary outcome measure was
depression severity according to the Hamilton Depres-
sion Rating Scale (HDRS).
Risk of bias assessment (RCTs)
The risk of bias in RCTs was assessed using the criteria
proposed by Cochrane [26]. The outcomes of this assess-
ment for each individual study are shown in Table 5.
Results
Study details (Tables 2 and 3)
Our review comprises k = 9 studies including k = 5 studies
with open-label designs and k = 4 double-blind RCTs with
sham control groups. Of all 148 participants, n = 84 re-
ceived active high-frequency (10–20 Hz) DTMS, n = 50
sham treatment, and n = 14 low-frequency (1 Hz) DTMS.
Fig. 1 Study selection procedure (PRISMA flowchart). Note. Abbreviations: k, number of studies; SUD, substance use disorders
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male. Substance-related diagnoses included alcohol use
disorders (AUD) in k = 6 studies (n = 39 DTMS, n = 15
sham), nicotine dependence (k = 1; n = 32 high-frequency
DTMS, n = 14 low-frequency DTMS, n = 31 sham), and
cocaine use disorders (CUD; k = 2, n = 13 DTMS, n = 4
sham). The participants in all studies were seeking treat-
ment for their SUD and were recruited from the general
population or from clinics specializing in SUD. Most were
heavy, long-term users of alcohol, nicotine or cocaine
(average use of 10–46 years) who either did not success-
fully respond to or relapsed after other treatments. DTMS
was administered either as an add-on therapy to antide-
pressants and/or to mood stabilizers in k = 5 open-label
studies or as a monotherapy in k = 4 RCTs.
The last follow-up assessments were conducted at 2–
12 months after the last acute DTMS sessions. Once the
course of daily stimulation ended, there was no mainten-
ance DTMS treatment in any of the studies. Substance-
related cues were presented before DTMS in two studies
with AUD or nicotine use disorders, respectively [18, 20].
Stimulation parameters (Table 4)
The majority of studies utilized H1 coil (k = 7) and a
high frequency/intensity (10–20 Hz/100–120% of the
resting motor threshold, MT) stimulation protocol
applied for 10–20 acute (daily or almost daily) sessions.
One study [18] also included a low-frequency (1 Hz)
stimulation protocol with 120% MT and 13 sessions.
Risk of bias in the RCTs (Table 5)
The quality of the k = 4 RCTs was acceptable in terms of
randomization, blinding, and reporting of results. How-
ever, the outcome assessment was problematic (under-
powered) in three RCTs due to small sample sizes andhigh attrition. Furthermore, two of the four RCTs were
industry-sponsored.
DTMS and SUD (Table 6)
The results synthesized from all k = 9 studies suggest
that overall the high-frequency DTMS was effective at
treating various symptoms of different SUD, both acutely
and in the longer term (Table 6).
Alcohol outcomes
DTMS with H1-coil consistently alleviated AUD symp-
toms, particularly in k = 4 open-label studies with co-
morbid AUD and MDD. Specifically, alcohol craving
and/or urge was acutely reduced after DTMS (20 ses-
sions/18–20 Hz/120% MT) relative to baseline and at
follow-up (6–12 months) relative to baseline. In
addition, depression severity was also alleviated, both
acutely and at follow-up (6–12 months) relative to base-
line in all k = 4 studies.
The acute effects of DTMS were also reported in k = 2
RCTs with inactive sham that included AUD cases with-
out MDD [20, 25]. Daily use was reduced in both RCTs
after DTMS relative to baseline or to sham. However,
alcohol craving was acutely reduced in only one of the
RCTs [20] with a higher frequency/intensity protocol (10
sessions/20 Hz/120% MT) relative to baseline or to sham.
The effects of active DTMS relative to sham were not
computed and no change in craving was acutely observed
after DTMS with lower frequency/intensity (12 sessions/
10 Hz/100% MT) relative to baseline in the other RCT
[25]. Although the longer-term effects of DTMS on AUD
could not be reliably established due to a high drop-out
rate in one RCT [20], craving and consumption tended to
remain lower in the active DTMS group at follow-up



























































































































































































































































































































































































































































































































































































































































































































































































































































Kedzior et al. BMC Psychiatry  (2018) 18:137 Page 4 of 11
Table 3 Study design and SUD assessment in k = 9 studies






Study design Study groups
Alcohol
Rapinesi et al., 2013 [17] OCDS Session 20 6 months add-on open-label
(case study)
1 group: DTMS
Rapinesi et al., 2014 [19] OCDS Session 20 12 months add-on open-label
(case study)
1 group: DTMS
Ceccanti et al., 2015 [20] VAS, TLFB,
blood prolactin
Session 10 2–3 months monotherapy RCT 2 groups (both with cue
conditionc): DTMS vs. sham
Girardi et al., 2015 [21] OCDS Session 20 6 months add-on open-label 2 groups: DTMS vs. STD
(no DTMS)
Rapinesi et al., 2015 [22] OCDS Session 20 6 months add-on open-label 2 groups: DTMS (MDD + AUD)
vs. DTMS (MDD)
Addolorato et al., 2017 [25] OCDS, ADS,
TLFB, SPECT
Session 12 – monotherapy RCT 3 groups: DTMS vs. sham vs.
healthy (no DTMS)
Nicotine
Dinur-Klein et al., 2014 [18] FTND, sTCQ,
urine analysis
Session 13 6 months monotherapy RCT 6 groups (each with or without
cue conditionc): DTMS (10 Hz)
vs. DTMS (1 Hz) vs. sham
Cocaine
Bolloni et al., 2016 [24] Hair analysis Session 12 6 months monotherapy RCT 2 groups: DTMS vs. sham
Rapinesi et al., 2016 [23] VAS Session 12 2 months add-on open-label 1 group: DTMS
aThere was no maintenance DTMS treatment during the follow-up phases
bAdd-on means that DTMS was administered in addition to concurrent pharmacotherapy
cThe cue condition consisted of a substance-related stimulus (e.g. raising a glass filled with a favourite alcoholic drink) prior to DTMS
ADS Alcohol Dependence Scale [41], DTMS deep transcranial magnetic stimulation, FTND Fagerström Test for Nicotine Dependence [42], HDRS
Hamilton Depression Rating Scale [43], k number of studies, OCDS Obsessive Compulsive Drinking Scale [44], RCT double-blind randomised
controlled trial with inactive sham control group, SDT standard drug treatment, SPECT single photon emission computed tomography, sTCQ the
short Tobacco Craving Questionnaire [45], SUD substance use disorder, TLFB Timeline Followback Interview (assessment of consumption) [46], VAS
visual analogue scale for craving [47]
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toms (with scales or self-reported frequency of use), both
RCTs also reported acutely reduced dopamine activity
using biological measures. Specifically, blood cortisol
and prolactin levels (markers of dopamine activity) were
reduced after DTMS relative to baseline or to sham [20]
and striatal dopamine transporter (DAT) availability
(measured with the single photon emission computed
tomography, SPECT) was reduced after DTMS relative
to baseline [25].Nicotine outcomes
Only one study (RCT with inactive sham) [18] assessed
the effects of DTMS with HADD-coil on nicotine use.
Although nicotine craving did not differ acutely after
DTMS relative to sham, acute nicotine consumption and
dependence were reduced and abstinence increased in
the high-frequency DTMS groups (13 sessions/10 Hz/
120% MT), in particular when DTMS was preceded by a
smoking-related cue, relative to sham [18]. The reduc-
tion in nicotine consumption and continuous abstinence
were also observed in the high-frequency DTMS groups
at follow-up (6 months) relative to sham [18]. Incontrast, low-frequency DTMS (1 Hz) had poor efficacy
and was discontinued [18].
Cocaine outcomes
The effects of DTMS with H1-coil on CUD were
assessed in k = 2 studies (one RCT [24] and one open-
label study [23]). Cocaine consumption (detected in hair)
and craving were acutely reduced after DTMS (12 ses-
sions/10–15 Hz/100% MT) relative to baseline and at
follow-up (2–6 months) relative to baseline. However,
there was no difference in cocaine consumption between
the active DTMS relative to sham in the RCT [24].
Safety
All patients completed the treatment with DTMS in six
out of k = 9 studies included in this review. However,
high drop-out rates were reported in k = 3 studies
(Table 2). The authors of these studies claimed that
DTMS is safe because no severe side-effects occurred.
Mild adverse reactions to DTMS (headaches, nausea,
discomfort) were reported in nine participants in k = 2
studies [18, 24]. Others dropped out due to relapse in
SUD or other factors unrelated to treatment, such as
inconvenience and other personal reasons.
Table 4 Stimulation parameters during acute (daily DTMS) phases in k = 9 studies

















Rapinesi et al., 2013 [17] H1 5.5 cm 20 120 – – 55 20 20
Rapinesi et al., 2014 [19] H1 5.5 cm 18 120 – – 55 20 20
Ceccanti et al., 2015 [20]c H1 5 cm 20 120 15,000 1500 30 30 10
Girardi et al., 2015 [21] H1 5.5 cm 20 120 – – 55 20 20
Rapinesi et al., 2015 [22] H1 5.5 cm 18 120 39,600 1980 55 20 20
Addolorato et al., 2017 [25]c H 5.5 cm 10 100 – – 20 15 12
Nicotine
Dinur-Klein et al., 2014 [18]c HADD 6 cm 10 120 12,870 990 33 20 13
HADD 6 cm 1 120 7800 600 33 20 13
Cocaine
Bolloni et al., 2016 [24]c H1 – 10 100 – – 20 15 12
Rapinesi et al., 2016 [23] H1 5.5 cm 15 100 – – 20 20 12
aPrefrontal cortex was stimulated in all studies
bDistance from the motor ‘hot-spot’
cActive stimulation parameters
DTMS deep transcranial magnetic stimulation, k number of studies, MT resting motor threshold
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Our review summarizes the preliminary evidence sug-
gesting that high-frequency DTMS might be a promising
treatment for cases with SUD who failed to respond to
other available treatments. According to data from nine
studies, craving, dependence, and consumption of alco-
hol, nicotine, and cocaine were reduced after daily treat-
ment with DTMS and some of these effects lasted for up
to 12 months without maintenance treatment. Although
highly interesting, the evidence to date should be inter-
preted with caution because it is based on studies with
open-label designs or RCTs with small sample sizes. Fur-
thermore, the interpretation of results in these studies is
difficult due to heterogeneous stimulation protocols, dif-
ferent SUD and SUD outcomes, and high drop-out rates
especially after cessation of daily treatment.
While the most optimal stimulation parameters for the
treatment of SUD remain unknown [14, 27], the current





















LOW LOW LOWalleviated following the high-frequency stimulation pro-
tocols. In particular, protocols with higher frequencies/
intensities (18–20 Hz, 120% MT) reduced alcohol crav-
ing and depression severity in comorbid AUD and
MDD, both acutely (after 20 sessions) and at follow-up
(6–12 months). Since such protocols produce consistent
acute antidepressant effects in MDD with AUD [10] but
also in MDD alone [2, 3], the acute reduction in AUD
symptoms might have been secondary to the alleviation
of MDD symptoms. However, the effects of DTMS
cannot be secondary alone because two RCTs without
comorbid MDD [20, 25] also reported acute reductions
in AUD symptoms after high-frequency DTMS. Thus,
high-frequency protocols may acutely reduce the severity
of both conditions (MDD and AUD). Protocols with
lower frequencies/intensities (10–15 Hz/100% MT) and
less daily sessions (10–13) also acutely reduced some
aspects of nicotine use and CUD symptoms although
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high-frequency, low-frequency DTMS (1 Hz) was inef-
fective at reducing nicotine use [18]. Similar to evidence
from rTMS studies [9, 11, 28], the efficacy of DTMS in
the treatment of SUD is likely to depend on the length
of stimulation in combination with frequency, intensity
as well as other stimulation parameters. For example,
DTMS outcomes in SUD may depend on the number of
stimuli that have been shown to influence the anti-
depressant outcomes of rTMS with F8-coil [29, 30]. Fur-
thermore, craving for some substances may be reduced
based on a complex mechanism requiring both excita-
tion with the high-frequency stimulation (10 Hz) and in-
hibition with the low-frequency stimulation (1 Hz)
according to preliminary evidence from an rTMS study
with F8-coil in methamphetamine users [28]. A higher
volume of primary data is required to investigate the
most optimal parameters of DTMS required for the
acute treatment of SUD using multivariate statistical
methods. It is also necessary to test the longer-term effi-
cacy of DTMS to improve treatment compliance and re-
duce relapse after daily treatment.
Although the general idea of applying non-invasive
brain stimulation to treat SUD symptoms is not new [9,
11, 27, 31, 32], the mechanism of action of these
methods, including DTMS, is still unclear. Past reviews
have shown that the high-frequency rTMS with F8-coil
is able to transiently reduce craving for various sub-
stances [9, 14, 32–35], possibly due to changes in the
dopamine and glutamate activity in the cortico-striato-
limbic systems implicated in SUD [9, 14, 15]. These
changes may include increased dopaminergic release
and/or improved dopaminergic binding in the striatum,
although multiple networks and neurotransmitter sys-
tems are likely to be involved depending on the type of
SUD [36]. In general, although various SUD affect com-
mon neural pathways, share common molecular targets,
and have similar reinforcing effects, they may access the
reward system via different mechanisms [15]. Advancing
efficient translational research is required to find new
pharmacological treatments for SUD [15]. The non-
invasive brain stimulation could be a viable alternative
to pharmacotherapy in the short-term and/or could offer
a longer-term relief from SUD although it may require
some individualization of protocols and/or stimulation
sites rather than the ‘one-size-fits-all’ approach [11]. In
fact, the unique shape of the H-coil that delivers a broad
cortical and presumably deeper, subcortical stimulation
[12, 37] may be particularly useful in the longer-term
treatment of SUD [38]. Indeed, the current review shows
that the effects of DTMS may last for up to 12 months
after daily stimulation phases despite the absence of
maintenance treatment. It has been suggested that re-
petitive stimulation is required for persistent andenduring plastic neuroadaptations [11, 31]. In fact, the
most consistent and longer-lasting plastic changes in
SUD may result from a combination of repetitive, broad,
and (presumably) deep stimulation achieved using H-
coils with high frequencies (18–20 Hz) and delivered for
at least 20 sessions. Such broad and deep stimulation
could affect both the multiple nodes of the executive
control network and the limbic network implicated in
craving [27]. The enhanced cognitive control could also
contribute to efficacy of DTMS in comorbid conditions,
such as MDD and SUD [36]. If DTMS improves cogni-
tion first [5], the recovery of executive functioning could
allow patients to subsequently regain cognitive control
over their substance craving, as well as their negative
mood states [22]. Future research is required to investi-
gate the neurobiological mechanisms and the interaction
between the cognitive outcomes and the alleviation of
SUD symptoms following DTMS. Furthermore, head-to-
head studies directly comparing the effects of various
coils (for example, F8-coil and H1-coil) in the treatment
of SUD are required to investigate which approach is
more effective.
While there is interest in finding new treatments for
SUD, the quality of evidence from DTMS studies is only
preliminary so far, similar to the evidence from rTMS
studies [9, 11]. The current review suggests that apart
from assessing various stimulation protocols and the
durability of the acute effects, other issues should also
be considered in the future DTMS research in SUD.
First, large, double-blind RCTs with inactive sham are
required to determine the efficacy of DTMS in the treat-
ment of various SUD. The studies reviewed here used
open-label designs (k = 5) while the four RCTs with
sham groups had only moderate quality at best. All stud-
ies reported a relatively low volume of data (only up to
11 cases received active DTMS treatment in eight out of
the nine studies) and/or high drop-out rates (33–50% in
three out of the nine studies). Therefore, the majority of
studies were underpowered and placebo and expectancy
effects were not controlled for. A preliminary meta-
analysis of the acute effects in studies included in the
current review showed a large pooled reduction in crav-
ing and dependence after active DTMS relative to base-
line (Hedges’ g = 2.65, 95% confidence interval: 1.28–4.
02, k = 5 studies [39]). However, this pooled effect was
not controlled for sham and there was a trend towards
higher effects in open-label studies relative to the RCTs
[39]. The effects of DTMS on SUD cannot be explained
by placebo/expectancy effects alone for a number of rea-
sons. Trends in the data suggest that DTMS was more
effective than sham for some symptoms of alcohol and
nicotine use disorders according to three RCTs reviewed
here. Furthermore, the subjective reports regarding the
reductions in SUD symptom severity after DTMS were
Kedzior et al. BMC Psychiatry  (2018) 18:137 Page 10 of 11confirmed with biological changes, including reductions in
either dopamine activity or concentrations of nicotine and
cocaine metabolites. Finally, despite the absence of mainten-
ance treatment, eight studies reported that some acute ef-
fects of DTMS on SUD tended to last for 2–12 months
after the last daily DTMS session. Second, future DTMS
studies need to carefully choose the outcome measures.
Most studies report the effects of non-invasive brain stimu-
lation on craving rather than the actual use [32]. The sub-
jective self-reports of substance use should also be verified
with biological assays. Although substance use tends to be
reliably and validly reported in anonymous research con-
texts [40], it may be underreported in the clinical practice.
Third, the clinical characteristics of patients could affect the
outcomes of DTMS studies in SUD. The efficacy of DTMS
may depend on SUD severity, concurrent pharmacotherapy,
and polysubstance use. Our review suggests that DTMS
may be most effective in combination with pharmacother-
apy for comorbid MDD and AUD or for cases with higher
severity of SUD. In contrast, DTMS as a monotherapy or
for cases with lower severity of SUD may produce less satis-
factory outcomes, possibly leading to higher dropout rates.
Polysubstance use also needs to be carefully controlled for
because H-coils targeting different neural regions may be
required for best efficacy depending on the substance and/
or the type of SUD. Finally, although no severe reactions to
DTMS were reported, a systematic assessment of DTMS
safety in SUD is necessary in future research.
There are a number of other limitations in the current re-
view. First, eight out of nine studies were conducted in Italy.
The clinical outcomes of DTMS on SUD symptoms need to
be tested in other institutions/countries. Second, the current
review considered only published literature from two aca-
demic databases. Although it is unlikely that other published
studies on the topic exist, currently ongoing studies may
provide higher-quality evidence regarding the use of DTMS
in the treatment of SUD. Third, the current review is de-
scriptive only and does not report any effect sizes. We con-
ducted a preliminary meta-analysis based on craving and
dependence outcomes using data from k = 5 studies [39].
The effect sizes were based on highly heterogeneous data,
including different study designs (open-label vs. RCT), SUD
types, outcome measures, and stimulation parameters.
Therefore, a larger volume of data is required for a more re-
liable meta-analysis of the effects of DTMS on SUD.
Conclusions
In conclusion, the current review provides preliminary
evidence that high-frequency DTMS may be effective at
treating some SUD symptoms both acutely and in the
longer-term (for 2–12 months after daily treatment).
Large RCTs with inactive sham are required to deter-
mine the efficacy and the optimal stimulation parame-
ters of DTMS for the treatment of different SUD.Abbreviations
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rTMS: Repetitive transcranial magnetic stimulation; SPECT: Single photon
emission computed tomography; sTCQ: The short tobacco craving
questionnaire; SUD: Substance use disorder (dependence and/or abuse);
VAS: Visual analogue scale for craving
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